Abstract: An animal rack system includes an animal monitoring assembly. The animal monitoring assembly includes a study region configured to receive an animal cage, a first emitter panel including a first two-dimensional array of first emitters, and a first receiver panel including a first two-dimensional array of first receivers. The first emitter panel and the first receiver panel are disposed on opposing sides of the study region. The first emitters are configured to emit first beams, and the first receivers are configured to receive emitted first beams from corresponding first emitters. The first receivers are further configured to generate first signals indicative of whether the first receivers received the emitted first beams. The animal monitoring assembly further includes a console configured to process the first signals to track an activity of a subject in the study region.

Abstract: The present invention relates to halogenated somatostatin analogs with selectivity for multiple somatostatin receptor subtypes and pharmaceutical compositions comprising the same. Moreover, the present invention relates to said halogenated somatostatin analogs and pharmaceutical compositions for use in therapy and/or diagnosis, for example in the treatment and/or diagnosis of diseases (e.g., cancer such as a neuroendocrine cancer) that are characterized by a high expression (e.g., overexpression) of one or more somatostatin receptor subtypes (e.g., somatostatin receptor 2 (SST2) and/or somatostatin receptor 5 (SST5)).

Abstract: An animal rack system includes an animal monitoring assembly. The animal monitoring assembly includes a study region configured to receive an animal cage, a first emitter panel including a first two-dimensional array of first emitters, and a first receiver panel including a first two-dimensional array of first receivers. The first emitter panel and the first receiver panel are disposed on opposing sides of the study region. The first emitters are configured to emit first beams, and the first receivers are configured to receive emitted first beams from corresponding first emitters. The first receivers are further configured to generate first signals indicative of whether the first receivers received the emitted first beams. The animal monitoring assembly further includes a console configured to process the first signals to track an activity of a subject in the study region.

Abstract: Methods, systems, and media including: receiving a list of summarized information characterizing a company; identifying, using a language model, at least one product feature within the summarized information; retrieving one or more opportunities; identifying, using the language model, at least one opportunity feature within the one or more opportunities; calculating, using a generative analytical engine, one or more similarity metrics that characterize the relationship between the at least one product feature and the at least one opportunity feature; and generating one or more product-opportunity pairs based on the one or more similarity metrics.

Abstract: Disclosed are PTHrP analogue formulations for transdermal delivery of a therapeutically effective amount of a PTHrP analogue, as well as transdermal patches prepared using these formulations, methods of preparing the disclosed formulations and patches, and methods of using these formulations and patches to treat osteoporosis, osteopenia, osteoarthritis, and/or bone fracture, improve bone mineral density (BMD), improve trabecular bone score (TBS), and treat, prevent, and/or reduce bone fractures.

Abstract: Provided herein are methods for treating osteoporosis and increasing bone mass density, that includes administering once a day, for about 5 minutes, a transdermal patch loaded with about 300 ?g of abaloparatide, and ZnCl2 at a molar ratio of 2.2:1 of ZnCl2:abaloparatide. Also provided are the single-use transdermal patches loaded with about 300 ?g of abaloparatide, and ZnCl2 at a molar ratio of 2.2:1 of ZnCl2:abaloparatide.

Abstract: Disclosed are abaloparatide formulations for transdermal delivery of a therapeutically effective amount of abaloparatide, as well as transdermal patches prepared using these formulations, methods of preparing the disclosed formulations and patches, and methods of using these formulations and patches to treat osteoporosis, osteopenia, osteoarthritis, and/or bone fracture, improve bone mineral density (BMD), improve trabecular bone score (TBS), and treat, prevent, and/or reduce bone fractures.

Abstract: Disclosed are abaloparatide formulations for transdermal delivery of a therapeutically effective amount of abaloparatide, as well as transdermal patches prepared using these formulations, methods of preparing the disclosed formulations and patches, and methods of using these formulations and patches to treat osteoporosis, osteopenia, osteoarthritis, and/or bone fracture, improve bone mineral density (BMD), improve trabecular bone score (TBS), and treat, prevent, and/or reduce bone fractures.

Abstract: A medical device comprising a composition comprising a therapeutically active amount of active agent, a zinc compound, and an array of microneedles. The zinc compound may be selected from the group consisting of zinc, pharmaceutically acceptable salts of zinc, and mixtures thereof. At least a portion of the composition is present as a coating on at least a portion of the microneedles. Methods of delivering a therapeutically active agent to a mammal using compositions of the disclosure are also included.

Abstract: A medical device comprising a composition comprising a therapeutically active amount of active agent, a zinc compound, and an array of microneedles. The zinc compound may be selected from the group consisting of zinc, pharmaceutically acceptable salts of zinc, and mixtures thereof. At least a portion of the composition is present as a coating on at least a portion of the microneedles. Methods of delivering a therapeutically active agent to a mammal using compositions of the disclosure are also included.

Abstract: Disclosed are abaloparatide formulations for transdermal delivery of a therapeutically effective amount of abaloparatide, as well as transdermal patches prepared using these formulations, methods of preparing the disclosed formulations and patches, and methods of using these formulations and patches to treat osteoporosis, osteopenia, osteoarthritis, and/or bone fracture, improve bone mineral density (BMD), improve trabecular bone score (TBS), and treat, prevent, and/or reduce bone fractures.

Abstract: Disclosed are abaloparatide formulations for transdermal delivery of a therapeutically effective amount of abaloparatide, as well as transdermal patches prepared using these formulations, methods of preparing the disclosed formulations and patches, and methods of using these formulations and patches to treat osteoporosis, osteopenia, osteoarthritis, and/or bone fracture, improve bone mineral density (BMD), improve trabecular bone score (TBS), and treat, prevent, and/or reduce bone fractures.

Abstract: Disclosed are abaloparatide formulations for transdermal delivery of a therapeutically effective amount of abaloparatide, as well as transdermal patches prepared using these formulations, methods of preparing the disclosed formulations and patches, and methods of using these formulations and patches to treat osteoporosis, osteopenia, osteoarthritis, and/or bone fracture, improve bone mineral density (BMD), improve trabecular bone score (TBS), and treat, prevent, and/or reduce bone fractures.

Abstract: Disclosed are PTHrP analogue formulations for transdermal delivery of a therapeutically effective amount of a PTHrP analogue, as well as transdermal patches prepared using these formulations, methods of preparing the disclosed formulations and patches, and methods of using these formulations and patches to treat osteoporosis, osteopenia, osteoarthritis, and/or bone fracture, improve bone mineral density (BMD), improve trabecular bone score (TBS), and treat, prevent, and/or reduce bone fractures.

Abstract: A medical device comprising a composition comprising a therapeutically active amount of active agent, a zinc compound, and an array of microneedles. The zinc compound may be selected from the group consisting of zinc, pharmaceutically acceptable salts of zinc, and mixtures thereof. At least a portion of the composition is present as a coating on at least a portion of the microneedles. Methods of delivering a therapeutically active agent to a mammal using compositions of the disclosure are also included.

Abstract: The present invention relates to isolated antibodies and antigen-binding fragments thereof which selectively bind human CD32b. Also provided herein are compositions comprising the antibodies or antigen-binding fragments thereof, methods of using the antibodies or antigen-binding fragments thereof, and methods of making the antibodies or antigen-binding fragments thereof.

Abstract: A handheld electric blower for stimulating and accelerating a fire includes: a hollow, generally cylindrical shaped body having a tapered, open front tip and an open rear end; a turbine blade positioned within the body; an electric motor positioned within the body and operationally coupled to the turbine blade; an adjustable baffle positioned within the front tip of the body; and a baffle control provided on an external surface of the body to adjust the position of the baffle to decrease or increase the flow of air through the body. Activation of the electric motor causes the turbine blade to rotate, thereby drawing air into the open rear end of the body and directing the air out of the tip.

Abstract: This invention provides a method for removing undesirable constituents from tobacco which includes extracting tobacco material in an aqueous or organic solvent and filtering the product of the extraction using a horizontal belt filter. The extract and insoluble tobacco residue may be further treated enzymically, chemically or otherwise to remove a complement of undesirable constituents. The extract and insoluble tobacco residue are recombined to form a regenerated tobacco material that is less harmful when combusted than the original material.

Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.